Pharmacist Remote Review of Medication Prescriptions for Appropriateness in Pediatric Intensive Care Unit by Moran Lazaryan et al.
ORIGINAL RESEARCH
published: 09 August 2016
doi: 10.3389/fphar.2016.00243
Frontiers in Pharmacology | www.frontiersin.org 1 August 2016 | Volume 7 | Article 243
Edited by:
Judith Ann Smith,
University of Texas Health Science
Center at Houston, USA
Reviewed by:
Matthew McLaughlin,
Children’s Mercy Hospital, USA
Rosalyn Sims,
Children’s Hospital of Michigan, USA
*Correspondence:
Matitiahu Berkovitch
mberkovitch@asaf.health.gov.il
†
These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Obstetric and Pediatric Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 31 May 2016
Accepted: 25 July 2016
Published: 09 August 2016
Citation:
Lazaryan M, Abu-Kishk I,
Rosenfeld-Yehoshua N, Berkovitch S,
Toledano M, Reshef I, Kanari T,
Ziv-Baran T and Berkovitch M (2016)
Pharmacist Remote Review of
Medication Prescriptions for
Appropriateness in Pediatric Intensive
Care Unit. Front. Pharmacol. 7:243.
doi: 10.3389/fphar.2016.00243
Pharmacist Remote Review of
Medication Prescriptions for
Appropriateness in Pediatric
Intensive Care Unit
Moran Lazaryan 1†, Ibrahim Abu-Kishk 2 †, Noa Rosenfeld-Yehoshua 2, Sofia Berkovitch 1,
Michal Toledano 1, Iris Reshef 2, Tal Kanari 2, Tomer Ziv-Baran 3 and Matitiahu Berkovitch 4*
1 Pharmacy Department, Assaf Harofeh Medical Center, Zerifin, affiliated to Sackler School of Medicine, Tel-Aviv University,
Tel-Aviv, Israel, 2 Pediatric Intensive Care Unit, Assaf Harofeh Medical Center, Zerifin, affiliated to Sackler School of Medicine,
Tel-Aviv University, Tel-Aviv, Israel, 3Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler
School of Medicine, Tel-Aviv University, Tel-Aviv, Israel, 4Clinical Pharmacology Unit, Assaf Harofeh Medical Center, Zerifin,
affiliated to Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Background: One aspect of ordering and prescribing medication is the requirement for
a trained professional to review medication orders or prescriptions for appropriateness.
In practice, this review process is usually performed by a clinical pharmacist. However, in
manymedical centers there is a shortage of staff and a pharmacist is not always available.
Objective: To determine whether remote review of medication orders by a pharmacist
is a plausible method in a pediatric intensive care unit (PICU).
Methods: A pharmacist from the pharmacy department reviewed medication orders
of patients admitted to our PICU over a 7-month period for appropriateness. A special
form for medical orders was filled in and sent to the physician in the PICU, who replied
informing whether the recommendation had been accepted. The time spent by the
pharmacist for this activity was recorded.
Results: The review time for one medical record was 8.9 (95% CI, 6.9–10.9) min. Every
additional drug prescribed increased the total review time by 0.8 (95% CI, 0.45–1.11)
min. The pharmacist filled in 186 forms on 117 admissions for 109 children. The
median review time was 15 (12.8–18.8) and 12 (9–15) min, respectively, for patients with
psychiatric-neurologic disorders compared to those without (p = 0.032). Usually, a daily
workload of 240 min was needed for the pharmacist accompanying the round in contrast
to 108 min per day needed to review all the medical records in 95% of the cases. The
physician accepted 51.2%, rejected 11.9%, and made no comment on 36.9% of the
recommendations.
Conclusion: Hospitals facing budget shortages can carry out focused remote reviews
of prescriptions by the pharmacist.
Keywords: medication review, pediatric intensive care, joint commission international, clinical pharmacist
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INTRODUCTION
Organizations in more than 100 countries are now working with
the Joint Commission International (JCI), which aims to improve
patient safety and quality of health care by offering education,
publications, advisory services and international accreditation
and certification. Many medical centers are keen to achieve
JCI accreditation and the organization has published standards
for hospitals regarding various aspects of patient care (Joint
Commission International, 2014, 5th Edn.). One of these sections
covers Medication Management and Use, which includes the
organization and management of medication, storing, ordering
and prescribing, preparing and dispensing, administration and
monitoring. One aspect of ordering and prescribing medication
is the requirement for a pharmacist, technician or trained
professional to review medication orders or prescriptions for
appropriateness. This process should be carried out before the
medication is administered to the patient and JCI standards say
that this should involve evaluating specific categories, namely
the appropriateness of the drug, the dose, frequency, route of
administration, therapeutic duplication, and drug interactions.
In practice, this review process is usually performed by a
clinical pharmacist joining physicians on their rounds (Lucca
et al., 2012). This process takes about 220 ± 40 min (mean 240)
based on random calculations made in our medical center during
the 6 month period prior to the study. However, in many medical
centers, as in ours, there is a shortage of staff and a pharmacist is
not always available. If no solution can be found, the relevant JCI
standards cannot not be met.
Since in our medical center there is a shortage of clinical
pharmacists, we carried out remote reviews by a pharmacist
located in the pharmacy department and not on the medical
ward. The department chosen for this purpose was the Pediatric
Intensive care Unit (PICU), as critically ill patients in general
(Moyen et al., 2008), and critically ill children in particular
(Miller et al., 2007; Zhang et al., 2012), are more prone to
medication errors.
The aims of our study were to evaluate the time needed by
the pharmacist to remotely review medication orders from the
pharmacy and to characterize the pharmacist recommendations
and the decisions taken by the physicians.
METHODS
This study was carried out at Assaf Harofeh Medical Center
with approval by the local ethics committee (Study number
84/14). Assaf Harofeh is a 900-bed tertiary hospital affiliated to
the Sackler School of Medicine, Tel-Aviv University, Israel. The
period of the current study lasted from 6 March 2014 until 6
October 2014. The setting was the seven-bed PICU. The medical
records of the PICU patients were computerized, except for the
medication orders, which were hand-written by the physician
on a separate document. Nurses copied the medication orders
onto a list on the nurses’ sheet and faxed a hard copy of the
updated medication list to the pharmacy every morning. An
experienced pharmacist reviewed medication orders from the
pharmacy department, without attending the PICU, during the
pharmacy department opening hours of 8 h a day, 5 days a week.
This task was in addition to routine work in the hospital. Software
was installed on every computer in the hospital, including the
pharmacy, which allowed remote access to the medical records
of the PICU patients.
A special form formedication orders, based on theMedication
Management and Use chapter of the JCI standards, was
constructed and specific categories were examined by the
pharmacist. After the pharmacist filled in the form, it was sent
to the senior physicians in the PICU, who sent back a detailed
response about whether the recommendation had been accepted
or not.
The demographics of each patient were recorded, including
age, weight, z-score (which is a standard score related to weight),
length of stay (LOS) in the hospital and in the PICU, reason for
hospitalization and the number of drugs prescribed.
Description of the Interventions
The interventions were divided into specific categories. The
pharmacist filled in a checklist, and added details about the
relevant reference in the medical literature.
“Using drugs according to the labeled indication” was examined
by comparing the medical diagnosis to the indication in the
Israeli labeling.
“There are no contra-indications to use the drugs in the patient”
was verified by the physician’s leaflet on prescribing information
and another evidence-based source, such as Micromedex
(Healthcare Series Truven Health Analytics Inc. Micromedex) or
Lexicomp’s Drug Reference Handbook.
“Appropriate dosage” included consideration of special
medical conditions such as renal failure.
“Appropriate frequency,” “appropriate route of administration,”
and “absence of therapeutic duplication,” were reviewed. Only
clinically significant interactions were reported and these were
classified as either major/contraindication by Micromedex or
rated as D = consider therapy modification or X = avoid
combination by Lexi-Interact. Additional comments regarding
the technical inappropriateness of the medication orders were
also documented, such as using forbidden abbreviations in the
medical order and missing details.
Another form was only filled in by the pharmacist when there
was any change in the medical treatment or a change in the
medical condition that required changing the medical treatment.
The pharmacist’s recommendation was only written and counted
once for the same admission, even if the physician rejected the
recommendation without explanation.
Statistical Analysis
Categorical variables were reported as numbers and percentages
and continuous variables were reported as means and standard
deviations (SD) or medians and interquartile ranges (IQR).
Continuous variables were tested for normal distribution using
the Kolmogorov–Smirnov test and Q-Q plots. Categorical
variables were compared using the chi-square test or Fisher’s
exact test and continuous variables by the independent
sample t-test or the Mann–Whitney test. Correlations between
continuous variables were evaluated using Spearman’s rank
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correlation coefficient. We used a univariate and multivariate
linear mixed model to evaluate the association between review
time and repeated reviews. The Monte Carlo simulation was
used to estimate the time needed to review the records of all
the patients each day. We used log-normal distribution for the
review time of each patient file and triangular distribution for the
daily capacity, based on a minimum of one bed, a maximum of
four and a mode of four. The simulation was based on 100,000
scenarios. In each Monte Carlo scenario, random sampling
was taken from each of the two distributions. A two-tailed
p < 0.05 was considered statistically significant. Analyses were
performed with SPSS version 21 (IBM Corporation, Armonk,
New York, USA).
RESULTS
Patient characteristics are described in Table 1.
During the study period, 186 review forms were filled in
by the pharmacist and sent to the physicians, regarding 117
admissions of 109 patients. There was at least one pharmacist
recommendation on 57 (30.6%) forms, with a total of 84
recommendations on all forms. The median age, percentile, and
sex of the patients did not differ significantly between those forms
that included recommendations and those that did not. However,
patients who received recommendations from the pharmacist on
their forms were prescribed more drugs and stayed longer in
the hospital and in the PICU than patients who did not receive
recommendations (Table 1).
The main reason for hospitalization among both groups
was infectious disease, accounting for 35.5 and 29.1% of
all patients with pharmacist recommendations and patients
with no recommendations, respectively. The main reason for
hospitalization did not differ significantly between the two
groups, except for psychiatric-neurological disorders, which were
more frequent in patients with pharmacist recommendations on
their forms (25.8 vs. 8.1%, p= 0.024).
The association between patient characteristics and review
time is presented inTable 2. Review time was recorded in the first
reviews of 79 out of 117 admissions. No statistically significant
association was found between review time and age (p = 0.238),
z-score weight (p= 0.852), percentile weight (p= 0.849), gender
(p= 0.167), and some main reasons for hospitalization.
However, the pharmacist spent a longer time reviewing
medication orders for patients with an infectious disease or
psychiatric-neurologic disorder. The median review time per
medical record was 15 min (range 10–16) for patients with
infectious diseases compared to 12 min (9–15) for patients with
no infectious disease (p = 0.049). The median review time
was 15 min (12.8–18.8) for patients with psychiatric-neurologic
disorders compared to 12 min (9–15) for patients with no
psychiatric-neurologic disorders (p= 0.032; Table 2).
The overall review time for each medical record was 8.9
min (95% CI, 6.9–10.9), and every additional drug prescribed
increased the total review time by 0.8 min (95% CI, 0.45–1.11).
The first assessment carried out showed that repeated reviews
of the same clinical case took longer than the first review by 0.85
min (95% confidence interval 0.12–1.59, p = 0.024). However,
after adjustment for the number of drugs prescribed in each
review, there was no correlation between the first and subsequent
reviews and the review time. Instead, a correlation was found
between the number of drugs and the review time.
Using the Monte-Carlo simulation, we estimated that 108
min per day were needed to review all the medical records for
this ward in 95% of the cases, assuming that the common daily
capacity in the PICU was four of the seven available beds, based
on a figure taken from the local computer control unit (Figure 1).
The most common pharmacist recommendations concerned
clinically significant interactions, which accounted for 34.5% of
all the recommendations, followed by dosage recommendations
(26.2%), contraindications (8.3%), drug-indication correlation
(3.5%), and frequency as well as route of administration
(2.38% each) and other comments (22.6%). There were no
recommendations regarding therapeutic duplication (Table 3).
The physicians accepted 43 (51.2%) of the 84
recommendations from the pharmacist, nine (10.7%) were
rejected with an explanation, one (1.2%) was rejected without an
explanation and there was no comment on 31 recommendations
(36.9%; Table 4).
There were 29 recommendations regarding clinically
significant drug interactions: in 17 (58.6%) cases the mechanism
of the interactions was changes in drug serum concentration, in
six (20.7%)—additive QT interval prolongation, in two (6.9%)
additive hyperkalemia and in the rest (13.8%) other mechanisms.
There were also 19 additional recommendations made by
the pharmacists and 14 (73.7%) of these concerned technical
inappropriateness of the medication order, such as unacceptable
abbreviations, missing information on route of administration
and dosage. A further five (26.3%) concerned inappropriate
details of specific terms for pro-re-nata scheduling.
DISCUSSION
According to the book of standards for hospitals published
by the JCI (Joint Commission International, 2014, 5th Edn.),
good medication management includes two reviews of each
prescription or order. One of the best options is that a clinical
pharmacist reviews the medication orders. However, many
medical centers cannot afford to employ the number of clinical
pharmacists needed, and therefore, are unable to meet the JCI
standard.
The role of clinical pharmacists in reducing medication errors
has been widely discussed in the literature. Interventions by
clinical pharmacists have been shown to improve patient safety,
satisfaction and compliance rates as well as decreasing adverse
drug events and the length of hospital stay (Leape et al., 1999;
Moffett et al., 2008; Makowsky et al., 2009; Klopotowska et al.,
2010; Cunningham, 2012; Kelishadi and Mousavinasab, 2012;
Zhang et al., 2012; Ho et al., 2013; Jiang et al., 2014; Zhai
et al., 2015). Some studies have shown considerable cost savings
(Krupicka et al., 2002; Larochelle et al., 2012; Lucca et al., 2012;
Michalets et al., 2015).
In the current study, the estimated time needed by an
experienced pharmacist, located in the pharmacy, to evaluate
the appropriateness of prescriptions requested for a seven-bed
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TABLE 1 | Characteristics of patients with and without pharmacist recommendations (PRs)a,b.
Study population Admissions without PRs Admissions with PRs p
n = 117 n = 86 n = 31
Age (months), median (IQR)c 31.5 (5.0–146.8) 29 (3.0–140.5) 35 (22.0–172.0) 0.103
Male, n (%) 73 (62.4%) 55 (64.0%) 18 (58.1%) 0.562
WEIGHT, MEAN (SD)d
Percentile 25.1 (2.9–56.1) 20.9 (2.9–55.8) 32.3 (3.1–65.2) 0.744
Z-score −0.9 (1.6) −0.9 (1.6) −0.8 (1.6) 0.903
MAIN REASON FOR HOSPITALIZATION, n (%)
Infectious diseases 36 (30.8%) 25 (29.1%) 11 (35.5%) 0.507
Respiratory disorders 10 (8.5%) 10 (11.6%) 0 (0.0%) 0.061
Post-operative invasive examination 10 (8.5%) 5 (5.8%) 5 (16.1%) 0.127
Fractures/injuries/accidents 19 (16.2%) 15 (17.4%) 4 (12.9%) 0.557
Medicines 3 (2.6%) 3 (3.5%) 0 (0.0%) 0.564
Cardiovascular 5 (4.3%) 5 (5.8%) 0 (0.0%) 0.323
Oncology 1 (0.9%) 1 (1.2%) 0 (0.0%) > 0.99
Endocrine disorders 3 (2.6%) 3 (3.5%) 0 (0.0%) 0.564
Psychiatric neurologic disorders 15 (12.8%) 7 (8.1%) 8 (25.8%) 0.024
Gastrointestinal disorders 10 (8.5%) 9 (10.5%) 1 (3.2%) 0.287
Burns 3 (2.6%) 1 (1.2%) 2 (6.5%) 0.171
Others 2 (1.7%)
NUMBER OF DRUGS, n (%)
1 12 (10.3%)
2 25 (21.4%)
3 13 (11.1%)
4 13 (11.1%)
5 15 (12.8%)
6 8 (6.8%)
7 11 (9.4%)
≥8 20 (17.1%)
Number of drugs, median (IQR) 4 (2.0–7.0) 3 (2.0–5.0) 7 (5.0–10.0) <0.001
Total LOS, median (IQR) 6 (3.0–9.0) 5 (3.0–8.0) 8 (6.0–13.0) 0.005
PICU LOS, median (IQR) 3 (2.0–5.0) 2 (1.0–4.0) 3 (2.0–8.0) 0.048
Review time (minutes), median (IQR) 13 (10.0–15.0) 12 (9.0–15.0) 15 (15.0–21.3) 0.001
aData refers to the first reviews of 117 admissions (109 patients).
bPR = at least one Pharmacist Recommendation.
c IQR = interquartile range.
dSD = standard deviation.
p = p-values. The p-values in Bold are those who were statistically significant.
PICU, with an average occupancy rate of four beds per day, was
108 min a day. This is in contrast to the same pharmacist being
present during the round with an average workload of 240 min
per day. Our method of medication assessment may save 45% of
the workload and salaries needed for clinical pharmacists.
The review time for one medical record was 8.9 min and every
additional drug prescribed increased the review time by 0.8 min
(95% CI 0.45–1.11). This time frame enabled the pharmacist to
perform other activities in the pharmacy.
In our study, the pharmacist made 84 recommendations
on 117 admissions of 109 patients, with 0.71 pharmacist
recommendations per admission and 0.77 per patient. The
most common recommendations concerned clinically significant
interactions and dosage recommendations. Critically ill patients
are often prescribed a large number of drugs with an increased
potential for drug interactions. Children are more prone to
medication errors (Wong et al., 2004; Miller et al., 2007), mostly
because the dosage is usually calculated based on age and weight,
in contrast to adults, where most drugs are usually prescribed as
a fixed dose.
Patients with pharmacist recommendations in our study
were prescribed more medications and had a longer total
hospital stay and a longer stay in the PICU. This may indicate
that patients requiring intervention from the pharmacist were
more severely ill. Other characteristics of the patients with
recommendations, in comparison to those without, have been
mentioned in other studies (Krupicka et al., 2002; Moffett
et al., 2008). These characteristics may help hospitals with
budget shortages to prioritize patients who require pharmacist
involvement.
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TABLE 2 | Association between patient characteristics and review time.
Review time (minutes)
n = admissionsa value p
Age (months), rbs 78 0.135 0.238
WEIGHT, rbs
Z-score weight 78 0.022 0.852
Percentile weight 78 0.022 0.849
Number of drugs, rs 79 0.395 <0.001
GENDER, MEDIAN (IQR)
Male 49 12.0 (9.0–15.0) 0.167
Female 30 13.0 (10.8–15.5)
MAIN REASON FOR HOSPITALIZATION, MEDIAN (IQR)
Infectious diseases
Absent 58 12.0 (9.0–15.0) 0.049
Present 21 15.0 (10.0–16.0)
Respiratory disorders
Absent 69 13.0 (10.0–15.0) 0.294
Present 10 11.5 (8.5–13.5)
Post-operative invasive examination
Absent 73 13.0 (10.0–15.0) 0.148
Present 6 10.0 (8.0–12.8)
Fractures/injuries/accidents
Absent 66 13.0 (9.8–15.0) 0.846
Present 13 12.0 (10.0–15.0)
Medicines
Absent 76 13.0 (10.0–15.0) 0.365
Present 3 12.0 (7.0–13.0)
Cardiovascular
Absent 75 13.0 (10.0–15.0) 0.254
Present 4 10.0 (7.8–13.8)
Oncology
Absent 78 12.5 (10.0–15.0) NA
Present 1 13.0 (13.0–13.0)
Endocrine disorders
Absent 78 12.5 (10.0–15.0) NA
Present 1 20.0 (20.0–20.0)
Psychiatric neurologic disorders
Absent 71 12.0 (9.0–15.0) 0.032
Present 8 15.0 (12.8–18.8)
GI disorders
Absent 71 13.0 (10.0–15.0) 0.436
Present 8 11.5 (8.5–13.0)
Burns
Absent 77 13.0 (10.0–15.0) NA
Present 2 12.0 (8.0–16.0)
PROPER FORMc
Absent 65 15.0 (15.0–21.3) 0.001
Present 14 12.0 (9.0–15.0)
aReview time was recorded in the first reviews of 79/117 admissions.
bData was available for 78/79 admissions.
cRefers to forms filled in by the pharmacist with no recommendations regarding the
medical treatment.
rs, Spearman’s rank correlation coefficient. p = p-values. The p-values in Bold are those
who were statistically significant.
Fourteen (16.6%) of the 84 recommendations in our study
concerned technical inappropriateness of the medical order,
such as using unaccepted abbreviations or missing details of
TABLE 3 | Pharmacist recommendations.
Pharmacist recommendations n %
Clinically significant interactions 29 34.52
Dosing recommendations 22 26.19
Additional comments 19 22.62
Contraindication 7 8.33
Drug-indication correlation 3 3.57
Frequency 2 2.38
Route of administration 2 2.38
the route of administration. These recommendations could have
been prevented had the medication order been computerized
rather than hand-written. Shulman et al. found that the
total proportion of medication errors was significantly lower
with computerized physician order entry (CPOE) than with
hand-written prescriptions (4.8 vs. 6.7%, respectively, p <
0.04; Shulman et al., 2005). Azizeh et al. found that using
CPOE with standardized concentrations decreased dispensing
errors on continuous infusion medications and required less
processing time than hand-written prescriptions (Azizeh et al.,
2010).
We assumed that remote reviewing of specific categories of
medical orders would take less time than that usually spent by the
clinical pharmacist on the ward. However, comparing the time
needed to review medical orders as reported in other studies was
problematic, because pharmacist intervention was not uniform.
The reported time was usually the routine daily time spent by the
pharmacist in the ward, rather than the time needed for reviewing
one medical record.
Krupicka et al. investigated the impact of a pediatric clinical
pharmacist in the 10-bed PICU (Krupicka et al., 2002). The
pharmacist made 172 recommendations for a total for 77
patients, with 2.23 recommendations per patient. It was reported
that patients with recommendations from the pharmacist had a
statistically significant longer length of stay in the PICU. The
most common pharmacist interventions reported were dosage
recommendations and drug information. The average time spent
by the clinical pharmacist in the PICU was 0.73 h per day.
Larochelle et al. described an 8-month review of clinical
pharmacist interventions in an 18-bed tertiary care PICU
(Larochelle et al., 2012). They reported an average of 5.5
interventions per patient, with dosage recommendations and
pharmacokinetics being the most common type of interventions.
The pharmacist was available for patient care rounds and follow-
up visits in the afternoon for 8 h a day for ∼12–15 days each
month.
The number of pharmacy recommendations per patient in
our study, which was 0.77, seemed lower than the numbers
reported in other studies. This could be explained by the fact
that the pharmacist focused on specific categories of drug
dispensing, rather than widespread counseling to the medical
staff. However, reviewing specific categories in the medical
treatment, as required by the JCI, is more practical than a
comprehensive review of medical orders, especially in hospitals
that have a shortage of pharmacists.
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FIGURE 1 | The estimated daily time needed to review all medication orders in the PICU.
TABLE 4 | Physician responses to pharmacist recommendations.
Pharmacist recommendations Total Accepted Rejected with explanation Rejected with no explanation No comment
n % n % n % n %
Drug-indication correlation 3 3.00 100.0 0 0.00 0 0.00 0.00 0.00
Contraindication 7 0.00 0.0 4 57.14 1 14.29 2.00 28.57
Dosing recommendations 22 11.00 50.0 4 18.18 0 0.00 7.00 31.82
Frequency 2 2.00 100.0 0 0.00 0 0.00 0.00 0.00
Route of administration 2 2.00 100.0 0 0.00 0 0.00 0.00 0.00
Therapeutic duplication 0 0.00 0.0 0 0.00 0 0.00 0.00 0.00
Clinically significant interactions 29 15.00 51.7 1 3.45 0 0.00 13.00 44.83
Additional comments 19 10.00 52.6 0 0.00 0 0.00 9.00 47.37
The physicians accepted 51.2% of pharmacist
recommendations, with 10.7% being rejected and in the
rest there was no comment. It is important to mention that
we classified a physician’s comment as a “rejection” when the
physician did not change the medicinal treatment despite of the
pharmacist note.
This includes two situations. Firstly, in cases of clinically
significant drug-drug interactions, which are frequently
inevitable in the context of PICU patients. Even though
the comments in such cases were classified as a rejection,
the physician was usually unaware of the existence of such
interaction and was grateful for the information. Secondly, we
also considered a comment as a “rejection” when the physician
kept prescribing a medicine despite a contraindication to its
use in certain conditions. Yet, it is important to mention that
the Israeli prescribing information frequently mentions more
contraindications than in the accepted literature. Moreover,
the pharmacist in our study carried out remote reviews,
which could explain the high percentage of recommendations
that the physicians did not comment on. We assume that
when the pharmacist is physically present in the ward, the
contact with the physician is closer, compared to electronic
or paper communication. A recent meta-analysis described
eight key elements reflecting effective collaboration between
a pharmacist and a general practitioner (GP). One of them
included face-to-face meetings to discuss drug-related
problems. The meta-analysis showed a significant association
between these key elements of the intervention and the
number of recommendations implemented (Kwint et al.,
2013).
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The limitations of this study include the relatively small
number of the participants, the fact that the severity of the illness
was not taken into consideration by the pharmacist and, the lack
of direct contact with the patient and his physician, whichmay be
the reason why some pharmacist recommendations were rejected
by the physicians. Yet the study’s significance lies in offering a
method to assess medications where there is a shortage of clinical
pharmacists.
CONCLUSIONS
In order to meet JCI standards there is a need for a
pharmacist review of the medication orders or prescriptions
for appropriateness. This time consuming process requires
budgets that are not always available. The current study
proposes a time saving method by showing that the assessment
of medication orders remotely by a pharmacist makes a
considerable contribution to the medical treatment. Hospitals
facing budget shortfalls can carry out focused remote reviews of
prescriptions by a pharmacist.
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